San Francisco, CA – October 26, 2026 – Geron Corporation has announced a significant strategic pivot in its development of Rytelo (imetelstat), a novel therapeutic agent for rare blood cancers. The company has elected to terminate the Phase III IMpactMF trial, a pivotal study evaluating Rytelo as a monotherapy in patients with intermediate-2 or high-risk myelofibrosis who are relapsed or refractory to a Janus kinase (JAK) inhibitor. This decision comes after the independent Data Monitoring Committee (DMC) recommended the discontinuation, forecasting that the trial was unlikely to meet its primary endpoint of significant improvements in overall survival (OS).
While the IMpactMF trial’s termination represents a notable setback for Geron’s monotherapy aspirations for Rytelo in this specific patient population, the company is emphasizing its renewed focus on exploring the drug’s combinatory potential. Specifically, Geron intends to investigate Rytelo in combination with Incyte and Novartis’ established JAK inhibitor, Jakafi (ruxolitinib), in the frontline myelofibrosis setting. This promising avenue is currently being explored in the ongoing Phase I IMproveMF trial.
The decision to halt IMpactMF, which had enrolled 327 patients across 144 global sites, underscores the rigorous nature of late-stage clinical trials and the critical role of independent oversight. The DMC’s recommendation was based on a pre-specified interim analysis, which suggested that Rytelo, when used alone in this heavily pre-treated patient group, would not demonstrate a statistically significant survival benefit compared to placebo or standard of care.
The Uphill Battle of Myelofibrosis and the Role of JAK Inhibitors
Myelofibrosis is a debilitating and often life-threatening myeloproliferative neoplasm characterized by the abnormal proliferation of hematopoietic stem cells and the progressive development of bone marrow fibrosis. This scarring disrupts the bone marrow’s ability to produce healthy blood cells, leading to a cascade of symptoms including severe fatigue, anemia, enlarged spleen (splenomegaly), bone pain, and a significantly reduced lifespan. The disease affects approximately one in 500,000 individuals worldwide, with a median survival ranging from 3 to 7 years depending on risk stratification.
For years, JAK inhibitors have been the cornerstone of treatment for intermediate and high-risk myelofibrosis. Jakafi, approved by the U.S. Food and Drug Administration (FDA) in 2011 for this indication, has revolutionized the management of the disease by effectively targeting the aberrant signaling pathways driven by mutated JAK proteins. Jakafi, known as Jakavi outside the United States, has become the standard of care (SoC) for a significant portion of the myelofibrosis patient population, generating substantial revenue for its developers. In 2025 alone, Jakafi generated an impressive $5.2 billion in global sales, highlighting its market dominance.
However, despite the efficacy of JAK inhibitors in managing symptoms and improving quality of life for many patients, a significant unmet need persists. Many patients eventually become refractory or relapsed to JAK inhibitor therapy, or their disease progresses to a more aggressive stage. These individuals have limited treatment options, and their prognosis remains poor. It was within this challenging landscape that Geron’s Rytelo was being evaluated as a potential monotherapy in the IMpactMF trial.
Chronology of the IMpactMF Trial and the DMC’s Recommendation
The Phase III IMpactMF trial, registered under ClinicalTrials.gov identifier NCT04576156, was designed to rigorously assess the efficacy and safety of Rytelo in patients with myelofibrosis who had previously failed or were intolerant to JAK inhibitor treatment. The trial’s primary endpoint was overall survival, a critical measure of treatment benefit in oncology. Secondary endpoints included spleen response, symptom burden reduction, and progression-free survival.
The trial commenced with Geron’s ambition to establish Rytelo as a valuable therapeutic option for a population with significant unmet needs. The recruitment of 327 patients across 144 international sites demonstrated the global commitment to advancing research in myelofibrosis. Throughout the trial, patient safety was closely monitored, and the DMC played a crucial role in overseeing the accumulating data.
The independent DMC, comprised of leading hematologists and statisticians, convened periodically to review unblinded safety and efficacy data. Their mandate is to protect patient welfare and ensure the scientific integrity of the trial. In their recent review, the committee observed trends that indicated Rytelo was unlikely to achieve its primary objective of significantly improving overall survival in the monotherapy setting for this patient group. This assessment, based on the totality of the data available at that interim point, led to their recommendation for trial discontinuation.
"Given the recommendation from the DMC, we believe discontinuing our Phase III IMpactMF trial at this time is the right course of action," stated Dr. Joseph Eid, Geron’s Chief Medical Officer and Executive Vice President of R&D, in a press release. "While this decision is disappointing, it is grounded in scientific rigor and our commitment to prioritizing patient well-being. We will now thoroughly evaluate the comprehensive data generated from IMpactMF to glean valuable insights that can inform future research in myelofibrosis."
Crucially, the DMC’s assessment did not identify any new safety signals associated with Rytelo’s use in the IMpactMF trial. This finding is a positive indicator for the drug’s safety profile, particularly as Geron pivots towards exploring its combination potential.
Supporting Data and Geron’s Future Strategy: The Promise of Combination Therapy
While the IMpactMF trial did not meet its primary endpoint as a monotherapy, Geron is not abandoning Rytelo’s potential in myelofibrosis. Instead, the company is strategically shifting its focus to investigating Rytelo’s efficacy when used in combination with existing therapies, most notably Jakafi. This approach acknowledges the complex biology of myelofibrosis and the potential for synergistic effects when multiple therapeutic mechanisms are employed.
The Phase I IMproveMF trial is currently evaluating Rytelo in combination with Jakafi in the frontline myelofibrosis setting. This trial aims to establish the safety, tolerability, and preliminary efficacy of this combination therapy in patients who have not yet received any treatment for their myelofibrosis. By targeting both JAK signaling pathways and telomerase, Rytelo’s mechanism of action, Geron hopes to achieve a more profound and durable response than either drug alone.
Rytelo, originally approved by the FDA in 2024 for lower-risk myelodysplastic syndrome (MDS) in patients who are unresponsive or ineligible for erythropoiesis-stimulating agents, represents a novel approach to treating hematologic malignancies. Its mechanism involves inhibiting telomerase, an enzyme essential for cell division and proliferation, thereby potentially limiting the growth of cancer cells. This distinct mechanism offers a compelling rationale for its exploration in combination regimens.
Analysts at GlobalData, the parent company of Clinical Trials Arena, have projected a strong commercial future for Rytelo, forecasting global sales of $1.2 billion by 2032. This projection likely accounts for its established indication in MDS and its potential expansion into other hematologic cancers, including myelofibrosis, particularly in combination settings.
Official Responses and Industry Perspectives
Geron’s announcement has been met with a measured response from the scientific and investment communities. While the discontinuation of a Phase III trial is always a significant event, the company’s proactive communication and clear articulation of its revised strategy have helped to mitigate potential negative sentiment.
Dr. Eid’s statement emphasizes Geron’s commitment to scientific integrity and patient welfare, underscoring that the decision was based on robust data and expert recommendations. The company’s intent to share insights from the IMpactMF trial further demonstrates a dedication to advancing the collective understanding of myelofibrosis treatment.
The pharmaceutical industry often sees such strategic adjustments as a normal part of drug development. The complexity of diseases like myelofibrosis frequently necessitates exploring various therapeutic approaches, including monotherapy and combination strategies. The success of Jakafi in the myelofibrosis market also highlights the significant commercial potential for therapies that can effectively address this patient population.
Implications for the Myelofibrosis Landscape and Future Research
The termination of the IMpactMF trial has several key implications for the myelofibrosis treatment landscape:
- Shifting Monotherapy Focus: It signals a potential downplaying of Rytelo as a standalone treatment for relapsed/refractory myelofibrosis patients who have failed JAK inhibitors. This segment of the market remains a significant challenge, and the failure of IMpactMF suggests that novel monotherapy approaches may face substantial hurdles.
- Elevated Importance of Combination Therapy: Geron’s commitment to the IMproveMF trial, exploring Rytelo with Jakafi, now becomes a critical focal point. The success of this combination could redefine frontline treatment strategies for myelofibrosis and unlock significant market potential for Rytelo.
- Continued Innovation in Myelofibrosis: The myelofibrosis field is not standing still. The article highlights other promising agents in development, such as Karyopharm’s Xpovio (selinexor), which has shown potential additive benefits to standard of care in JAK inhibitor-naïve patients, and Eli Lilly’s AJ1-11095, a JAK2 inhibitor acquired through a significant acquisition, which has demonstrated encouraging early-stage results. These ongoing developments underscore the dynamic nature of research in this area and the continuous pursuit of improved patient outcomes.
- Value of Data Analysis: The emphasis on evaluating and sharing data from the IMpactMF trial is crucial. Even in cases of trial termination, the data collected can provide invaluable insights into disease biology, patient responses, and potential biomarkers, which can inform future trial designs and therapeutic strategies.
In conclusion, while Geron Corporation faces a significant hurdle with the discontinuation of the IMpactMF trial, the company’s strategic pivot towards combination therapy with Rytelo and Jakafi offers a compelling path forward. The myelofibrosis market is ripe for innovation, and the development of effective combination regimens holds the promise of significantly improving the lives of patients battling this rare and devastating blood cancer. The coming years will be critical in determining whether Rytelo can fulfill its potential as a valuable component of a multi-pronged approach to managing myelofibrosis.
About the Author
